CSL Ltd Annual Report 2019

Leveraging advanced analytics and artificial intelligence Data science and artificial intelligence (AI) and their potential to help patients is one of the most discussed topics in healthcare. Data science and AI can potentially decrease the time for patients to receive an accurate diagnosis and help doctors home in on precise treatments. CSL is pushing to go further by implementing the use of data science in almost every aspect of our operations. It’s a strategic shift that will strengthen our ability to deliver on our promise to patients. A demonstrated commitment CSL is taking a two-pronged approach to integrating AI into the organisation. Dozens of data scientists are working on projects throughout CSL as part of a Centre of Excellence on advanced analytics and AI. Leaders in various parts of the company who are interested in launching AI initiatives comprise a Community of Practices that can consult the data science team to make sure their plan is the right one for their team and for CSL as a whole. A global approach In April, CSL brought together more than 150 of its data science stakeholders for the organisation’s first-ever data science summit. The gathering included presentations from CSL leaders on how CSL is integrating data science in everything it does, from developing lifesaving therapies to improving supply chain efficiency. Innovation across the value chain Innovation is sparked by a need and a great idea. Bringing an idea to life requires a strong chain in which each link is essential. We deliver on our promise by prioritising ideas, funding those ideas, giving those ideas life through our medicines, and getting those products to the patients who need them. Innovation across the value chain goes far beyond R&D. We innovate to enhance experiences, efficiency and excellence for patients and their communities, as well as our employees and their communities, adding value that improves their quality of life. IDELVION is becoming the new standard of care for haemophilia B as the only treatment approved by the US FDA for up to 14-day dosing to prevent and control bleeding. Longer dosingmeans patients don’t have to infuse as often. IDELVION is now offered in five vial sizes in the US to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU. The larger size will save time for patients who previously needed to prepare multiple vials for a similar dose, a process that involves set up, sterilisation and mixing. Less reconstitution time pays off in improved convenience which may decrease the potential of patients skipping their treatments. Enhanced convenience for haemophilia B patients CSL Behring is focused on reducing the burden of care and improving life for people with haemophilia. IDELVION ® is helping patients with haemophilia B to spend less time preparing and infusing their medicine and more time leading fuller lives. A key takeaway from CSL’s first data science summit was the critical role that AI and data science is playing in CSL’s digital transformation and continued growth. Leaders across the organisation shared a common message: data science is essential to CSL’s future success. CSL Limited Annual Report 2019 19